Acrivon Therapeutics, Inc. Common Stock Stock Analysis & AI Score
Acrivon Therapeutics, Inc. Common Stock (ACRV) has an ST Score of 45.7 (C+), driven by its Forecast (A) and held back by its Growth (D-). Analysts rate it Buy with a $21.83 price target (+929.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Acrivon Therapeutics, Inc. Common Stock (ACRV) has an ST Score of 45.7 (C+), driven by its Forecast (A) and held back by its Growth (D-). Analysts rate it Buy with a $21.83 price target (+929.7% upside).
- Strongest
- ForecastA
- Weakest
- GrowthD-
All factor grades
- ForecastA
- MomentumB+
- ValuationB
- Financial StrengthB
- ProfitabilityD
- GrowthD-
- Piotroski1/9
Contact
ACRV stock: frequently asked questions
What is ACRV's ST Score?
Acrivon Therapeutics, Inc. Common Stock (ACRV) has an ST Score of 45.7 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ACRV a buy, hold, or sell?
Analysts rate ACRV a Buy, with a price target of $21.83 (+929.7% vs the current price). Our ST Score grades it C+ (45.7/100). The ST Score is a data-driven signal, not a recommendation.
What are ACRV's factor grades?
Valuation B, Profitability D, Financial Strength B, Momentum B+, Growth D-, Forecast A.
What is ACRV's valuation grade?
Acrivon Therapeutics, Inc. Common Stock (ACRV) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ACRV's growth grade?
Acrivon Therapeutics, Inc. Common Stock (ACRV) earns a growth grade of D-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ACRV's profitability grade?
Acrivon Therapeutics, Inc. Common Stock (ACRV) earns a profitability grade of D, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ACRV's financial strength grade?
Acrivon Therapeutics, Inc. Common Stock (ACRV) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ACRV?
The average analyst price target for Acrivon Therapeutics, Inc. Common Stock (ACRV) is $21.83 from 10 analysts, which is +929.7% versus the recent price of $2.12.
What is ACRV's Piotroski score?
Acrivon Therapeutics, Inc. Common Stock (ACRV) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.